Retatrutide Phase 3 Trials: What the Latest Research Shows in 2026

Retatrutide is one of the most closely followed investigational compounds in metabolic research. Developed by Eli Lilly, it is designed as a triple receptor agonist, targeting GIP, GLP-1, and glucagon receptors.

In 2026, new Phase 3 results provided researchers with more information about retatrutide’s effects on body weight, glycemic control, and obesity-related conditions.

What Is Retatrutide?

Retatrutide, also known as LY3437943, is an investigational peptide-based drug being studied for obesity, type 2 diabetes, and other metabolic conditions.

Unlike semaglutide, which mainly targets GLP-1 receptors, or tirzepatide, which targets GLP-1 and GIP receptors, retatrutide acts on three pathways:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

This triple-action mechanism is one reason retatrutide has attracted significant attention in metabolic research.

TRIUMPH-1: Retatrutide and Weight Loss

The Phase 3 TRIUMPH-1 trial studied adults with obesity or overweight without diabetes.

After 80 weeks, Eli Lilly reported average body-weight reductions of approximately:

• 19.0% with 4 mg
• 25.9% with 9 mg
• 28.3% with 12 mg
• 2.2% with placebo

At the 12 mg dose, participants lost an average of about 70 pounds.

These results suggest that retatrutide may produce substantial changes in body weight, although further long-term evaluation remains important.

TRIUMPH-2: Retatrutide and Type 2 Diabetes

The TRIUMPH-2 trial studied people with obesity or overweight who also had type 2 diabetes.

Reported weight reductions at 80 weeks reached approximately:

• 12.7% with 4 mg
• 19.1% with 9 mg
• 20.8% with 12 mg

Researchers also observed improvements in A1C levels, making this trial particularly relevant to metabolic and diabetes research.

TRIUMPH-3 and Cardiovascular Research

TRIUMPH-3 evaluated adults with severe obesity and established cardiovascular disease.

Participants receiving higher doses of retatrutide experienced average weight reductions above 20%.

However, cardiovascular event data from this study were not sufficient to establish whether retatrutide reduces cardiovascular risk. Larger and longer outcome studies are still underway.

What About Retatrutide Safety?

The most commonly reported side effects in Phase 3 studies were gastrointestinal.

These included:

• Nausea
• Diarrhea
• Constipation
• Vomiting

Some participants also reported altered skin sensations, known as dysesthesia.

As with any investigational drug, both effectiveness and safety must be evaluated together before regulatory approval can be considered.
Learn More about Retatrutide in detailed analysis.

Why Are Researchers Interested in Retatrutide?

Retatrutide is scientifically important because it combines three metabolic pathways into a single molecule.

Researchers are studying whether simultaneous activation of GIP, GLP-1, and glucagon receptors can produce broader metabolic effects than single- or dual-receptor compounds.

Current studies are exploring outcomes related to:

• Obesity
• Type 2 diabetes
• Cardiovascular health
• Kidney health
• Knee osteoarthritis
• Sleep apnea
• Metabolic liver disease

What Comes Next?

More Phase 3 studies are continuing, including large cardiovascular and kidney outcome trials.

These studies are important because researchers need to determine not only how much weight participants lose, but also whether retatrutide produces meaningful long-term improvements in overall metabolic health.

Final Thoughts

The latest Retatrutide Phase 3 trials in 2026 have strengthened scientific interest in triple-receptor agonists.

Studies such as TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 have reported significant changes in body weight and metabolic markers. However, retatrutide remains investigational, and additional safety, cardiovascular, and long-term outcome data are still needed.

At Zymera Labs, we follow emerging peptide research and clinical developments to help researchers stay informed about advances in peptide science and metabolic research.

For research and educational purposes only. This content is not medical advice and does not recommend the use of investigational compounds.